MARKET

AGEN

AGEN

Agenus
NASDAQ
2.930
-0.140
-4.56%
Opening 13:40 02/11 EST
OPEN
3.080
PREV CLOSE
3.070
HIGH
3.080
LOW
2.882
VOLUME
387.75K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
105.90M
P/E (TTM)
-1.4007
1D
5D
1M
3M
1Y
5Y
1D
Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors
Benzinga · 2d ago
Agenus Unveils New Data on Botensilimab Combination in Cold Tumors at AACR-IO Conference
Reuters · 2d ago
Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor
Reuters · 2d ago
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
Barchart · 2d ago
Weekly Report: what happened at AGEN last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at AGEN last week (0126-0130)?
Weekly Report · 02/02 10:36
Weekly Report: what happened at AGEN last week (0119-0123)?
Weekly Report · 01/26 10:36
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Agenus (AGEN) and Assertio Therapeutics (ASRT)
TipRanks · 01/21 15:30
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.